Intellectual Property India Publishes Patent Application for 'Antisense Oligonucleotides For The Treatment Of Hereditary Hfe-Hemochromatosis' Filed by Proqr Therapeutics II B. V.

MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517048344 A) filed by Proqr Therapeutics II B. V., Leiden, Netherlands, on May 20, for 'antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis.'

Inventor(s) include Potman, Marko; Yilmaz-Elis, Aliye Seda; and Kos, Aron.

The application for the patent was published on June 6, under issue no. 23/2025.

According to the abstract released by the Intellectual Property India: "The disclosure relates to the field of diseases caused by iron overload, such as homeostatic iron regulator protein (HFE) hemochromatosis. The disclosure provides oligonucleotides for RNA editing technology in targeting and deaminating the c.845GA nucleotide...